Scientific Online Resource System

Biomedical Reviews

Galectin-3: multiple clinical applications

Antoniya Kisheva, Yoto Yotov

Abstract

Galectin-3 is a β-galactoside binding lectin, containing carbohydrate-recognition domain, which interacts with a number of ligands. It is found in many tissues and is distributed intra– and extracellularly. The localization of the biomarker determines its function. Galectin-3 is involved in variety of biological processes sush as inflammation, fibrosis, immunological response and neoplastic growth. It may be used as a diagnostic or prognostic biomarker especially in cancer and cardiovascular diseases. The present review summarizes some of the properties of this biomarker.

Keywords

Galectin-3, inflammation, fibrosis, cancer, cardiovascular diseases, microtubules

Full Text


References

Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760:616–635. doi:10.1016/j.bbagen.2005.12.020

Fritsch K., Mernberger M., Nist A., Stiewe T., Brehm A, Jacob R. Galectin-3 interacts with components of the nuclear ribonucleoprotein complex, BMC Cancer, 2016; 16: 502. doi: 10.1186/s12885-016-2546-0.

Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One, 2013; 8(3): e59616. doi:10.1371/journal. pone.0059616

Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012; 946:21–36. doi: 10.1007/978-1-4614-0106-3_2.

Vasta GR. Roles of galectins in infection, Nat Rev Microbiol 2009; 7(6): 424–438. doi:10.1038/nrmicro2146.

Mey A., Leffler H., Hmama Z., Normier G, Revillard JP. The animal lectin galectin-3 interacts with bacterial mediators of inflammation lipopolysaccharides via two independent sites. J Immunol 1996; 156(4):1572–1577.

Fradin C, Jouault T, Mallet A, et al. Beta-1,2-linked oligoman-nosides inhibit Candida albicans binding to murine macrophage. J Leukoc Biol 1996; 60:81–87. https://doi. org/10.1002/jlb.60.1.81

Kohatsu L, Hsu DK, Jegalian AG, Liu FT, Baum LG. Galectin-3 induces death of Candida species expressing specific beta-1,2-linked mannans. J Immunol 2006; 177:4718–4726. doi:10.4049/jimmunol.177.7.4718

Radosavljevic GD, Pantić JM, Jovanović I, Lukic M, Arsenijević N. The two faces of Galectin-3: Roles in various pathological conditions. Ser J Exp Clin Res 2016; 17:187 - 198. doi: https://doi.org/10.1515/sjecr-2016-0011

Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. In-creased levels of galectin-3 were associated with predia-betes and diabetes: new risk factor? J Endocrinol Invest. 2015; 38(5):527-33. doi: 10.1007/s40618-014-0222-2.

Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation ofgalectin-3 suppresses tumorigenicity of human breast carcinomacells, Clin Cancer Res. 2001; 7:661–668.

Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001; 18:787–792. doi:10.1016/s0304-3835(03)00056-9.

Takenaka Y., Inohara H., Yoshii T, et al. Malignant trans-formation of thyroid follicular cells by galectin-3, Cancer Lett. 2003; 195:111–119

Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis, Apoptosis, 2005; 10:267-275 doi:10.1007/s10495-005-0801-y.

Yu F, Finley Jr RL, Raz A, Kim HR. Galectin-3 trans-locates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation J Biol Chem 2002; 277:15819-15827

Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol, 2004; 24: 4395-4406. doi:10.1128/mcb.24.10.4395-4406.2004

Fukumori T, Takenaka Y, Oka N, et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004; 64:3376-3379. doi:10.1158/0008-5472.CAN-04-0336

Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Can-cer Res 2003; 63:8302-8311

Kouo T, Huang L, Pucsek A, et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacy-toid Dendritic Cells, Cancer Immunol Res 2015; 3(4):412-423. doi: 10.1158/2326-6066.CIR-14-0150.

Fernandez G.C., Ilarregui J.M., Rubel CJ, et al. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alterna-tive MAPK pathways, Glycobiology 2005; 15:519–527. doi:10.1093/glycob/cwi026.

Funasaka T, Raz A, Nangia-Makker P. Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol. 2014; 27:30-8. doi: 10.1016/j.semcan-cer.2014.03.004.

Saravanan C, Liu FT, Gipson IK, Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci. 2009; 122(20):3684-93. doi: 10.1242/jcs.045674.

Zhao Q., Barclay M., Hilkens J, et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis, Mol Cancer 2010; 9:154. doi: 10.1186/1476-4598-9-154.

Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004; 165(6):1931-41. doi:10.1016/S0002-9440(10)63245-2

Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 2011; 286(34):29913-21. doi: 10.1074/jbc.M111.226423.

Wesley UV, Vemuganti R, Ayvaci ER, Dempsey RJ. Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling. Brain Res. 2013; 1496:1-9. doi: 10.1016/j. brainres.2012.12.008.

Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Commun. 2007; 363(2):336-41. doi:10.1016/j.bbrc.2007.08.179

Jia W, Kidoya H, Yamakawa D, Naito H, Takakura N. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol. 2013; 182(5):1821-31. doi: 10.1016/j.ajpath.2013.01.017.

Eliaz I, McKee D. Galectin-3 as an oncological biomarker. A review of its possible role in cancer treatment response and disease progression. Nat Med J. 2014; 6(9)

Liu H, D’Ambrosio M, Liao T, et al. N-acetyl-seryl-aspartyllysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol, 2009; 296:H404-412. doi:10.1152/ajp-heart.00747.2008.

Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-infl ammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol, 2008; 294:H1226-H1232. doi: 10.1152/ajp-heart.00305.2007

De Boer, RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the gen-eral population. J Intern Med 2012; 272(1):55-64. doi: 10.1111/j.1365-2796.2011.02476.x

Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coro-nary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem, 2012; 58(1):267-273. doi: 10.1373/clinchem.2011.174359

Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin -3 ,a novel marker of fi brosis , in patients with chronic heart failure: data from the DEAL-HF Study. Clin Res Cardiol. 2010; 99:323-328. doi: 10.1007/s00392-010-0125-y.

. De Boer RA , Lok DJ , Jaarsma T, et al. Predictive value of plasma galectin -3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011; 43:60-68. doi:10.3109/07853890.2010.538080.

De Filippi C., Christenson R., Shah R, et al. Clinical validation of a novel assay for galectin-3 for risk assessment in acutely destabilized heart failure. J Card Fail, 2009; 15:S9. doi: 10.1016/j.cardfail.2009.06.405

Ho JE, Yin X, Levy D, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014: 167:729–734 e721. doi: 10.1016/j.ahj.2014.02.009.

Sonmez О, Ertem FU, Vatankulu MA, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in nonvalvular atrial fibrillation. Med Sci Monit 2014; 20:463–470. doi:10.12659/MSM.890635.

Wu XY, Li SN, Wen SN, et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace. 2015; 17:1541–1547. doi: 10.1093/europace/euv045.

Kornej J., Schmidl J., Ueberham L, et al. Galectin-3 in Pa-tients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation. PLoS ONE. 2015; 10(4):e0123574. doi:10.1371/journal.pone.0123574.

He B., Huang B, Lu Z, He W, Jiang H. Galectin-3: a potential new target for upstream therapy of atrial fibril-lation. Int J Cardiol 2016; 203:1131–1132. doi:10.1016/j. ijcard.2015.09.058.

Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al. New onset atrial fibrillation is associated with elevated galectin-3 levels. Int J Cardiol. 2016: 223, 48-49. doi: 10.1016/j.ijcard.2016.08.172

Clementy N, Piver E, Benhenda N, Bernard A, Pierre B, Simeon E, et al. Galectin-3 in patients undergoing abla-tion of atrial fibrillation . IJC Metab Endocr 2014: http://dx. doi.org/10.1016/j.ijcme.2014.10.003.

Kisheva A. Role of fibrosis and blocking of mineralcor-ticoid receptors in atrial fibrillation. PhD Thesis, 2017, Medical University, Varna, Bulgaria.

Bouguenina H, Salaun D, Mangon A, Muller L, Baudelet E , Camoin L , et al . EB 1 -binding -myomegalin protein complex promotes centrosomal microtubules functions . Proc Natl Acad Sci USA . 2017 ;114 (50):E 10687-E10696. doi: 10.1073/pnas.1705682114.

Clare DK, Magescas J, Piolot T, Dumoux M, Vesque C, Pichard E, et al. Basal foot MTOC organizes pillar MTs required for coordination of beating cilia. Nat Commun 2014;5:4888. doi: 10.1038/ncomms5888.

Albrethsen J, Angeletti RH, Horwitz SB, Yang CP. Proteomics of cancer cell lines resistant to microtubule-stabilizing agents. Mol Cancer Ther 2014;13(1):260-269. doi: 10.1158/1535-7163.MCT-13-0471

Yanev S, Fiore M, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev 2016;27: 59-67.

Natale A, Elayi CS . Colchicine for prevention of post-cardiac procedure atrial fibrillation : Meta -analysis of randomized controlled trials . Int J Car diol 2017; 243:258-262.

Chaldakov GN. Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases. Cell Biol Int 2018; 42(8):1079-1084. doi:10.1002/cbin.10988




DOI: http://dx.doi.org/10.14748/bmr.v30.6389

Refbacks

Article Tools
Email this article (Login required)
About The Authors

Antoniya Kisheva
Medical University of Varna
Bulgaria

First Department of Internal Diseases, ES Cardiology

Yoto Yotov
Medical University of Varna
Bulgaria

First Department of Internal Diseases, ES Cardiology

Font Size


|